MCID: FLL037
MIFTS: 73

Follicular Lymphoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Follicular Lymphoma

MalaCards integrated aliases for Follicular Lymphoma:

Name: Follicular Lymphoma 12 73 20 36 29 6 15 37 32
Lymphoma, Follicular 20 44 70
Lymphoma Follicular 54

Classifications:



Summaries for Follicular Lymphoma

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 545 Definition Follicular lymphoma is a form of non-Hodgkin lymphoma (see this term) characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved. Epidemiology Prevalence of follicular lymphoma is estimated at about 1/3,000. Clinical description The median age at diagnosis is 60-65 years. The disease is extremely rare in children. Follicular lymphoma is located primarily in the lymph nodes, but can also involve the spleen, bone marrow, peripheral blood and Waldeyer's ring. The skin and central nervous system are affected in rare cases. Symptoms appear at an advanced stage of the disease and can include fever, night sweats and weight loss. At diagnosis, patients usually present with adenopathy and, in 50% of cases, splenomegaly. Etiology In 85% of cases, follicular lymphomas are associated with a translocation t(14;18) (q32;q21), which activates the BCL2 gene encoding the BCL2 protein that is essential for some apoptosis processes. Diagnostic methods Diagnosis is based on histological analysis of the adenopathy, a complete blood count, measurement of lactate dehydrogenase (LDH) and biopsy analysis of a lymph node. Examination using imagery (particularly a chest radiograph) is required. The observation of the translocation t(14;18) by polymerase chain reaction (PCR), in addition to suggested histological results, confirms the diagnosis. Differential diagnosis Differential diagnoses include chronic lymphocytic B cell leukemia, diffuse large B cell lymphoma, mantle cell lymphoma and MALT lymphoma (see these terms). Management and treatment If the lymphoma is localized it should be treated by radiotherapy. In the case of advanced stage lymphoma, chemotherapy with immuno-chemotherapy should be offered (rituximab combined with CHOP). In cases of chemosensitive relapse, treatment can be intensified. Prognosis The survival rate at five years is 80-90% and medial survival is approximately 10-12 years.

MalaCards based summary : Follicular Lymphoma, also known as lymphoma, follicular, is related to follicular lymphoma 1 and lymphoma. An important gene associated with Follicular Lymphoma is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are DNA Damage Response and DNA Damage Response (only ATM dependent). The drugs Neuroprotective Agents and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, b cells and t cells, and related phenotypes are fever and lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has material basis in follicle center B-cells (centrocytes and centroblasts).

KEGG : 36 Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by diffuse lymphoadenopathy, bone marrow involvement, splenomegaly, and less commonly other extranodal sites of involvement. The genetic hallmark of FL, the translocation t(14;18)(q32;q21), results in the constitutive overexpression of the bcl 2 protein, which impairs the normal germinal centre apoptotic programme. Inactivating mutations of MLL2 are found in >80% of FL and interfere with the ability of MLL2 to activate gene transcription through H3K4 methylation. Mutations of other histone modifiers (CREBBP, EZH2, MEF2B, and EP300) are found in ;33%, 27%, 15%, and 9% of FL, respectively.

Wikipedia : 73 Follicular lymphoma (FL) is a cancer that involves certain types of white blood cells known as... more...

Related Diseases for Follicular Lymphoma

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 550)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 1 33.2 FL1 BCL6 BCL2
2 lymphoma 32.0 ZC3H12D MYC KDSR CCND1 BCL6 BCL2
3 b-cell lymphoma 31.8 MYC MME MIR155 CCND1 BCL6 BCL2
4 lymphoma, hodgkin, classic 31.7 MIR155 BCL6 BCL2
5 marginal zone b-cell lymphoma 31.5 MME CCND1 BCL6 BCL2 BCL10
6 nodal marginal zone b-cell lymphoma 31.5 BCL6 BCL2
7 lymphoblastic lymphoma 31.4 MYC MME BCL6
8 lymphoma aids related 31.4 MYC BCL6
9 burkitt lymphoma 31.4 MYC MME MIR155 BCL6 BCL2 AICDA
10 lymphosarcoma 31.3 BCL6 BCL2
11 mantle cell lymphoma 31.3 MYC MME MIR155 CCND1 BCL6 BCL2
12 plasmablastic lymphoma 31.2 MYC BCL6
13 diffuse large b-cell lymphoma of the central nervous system 31.2 MYC BCL2
14 lymphoma, non-hodgkin, familial 31.1 MYC MME MIR338 MIR181A1 MIR155 MIR149
15 cll/sll 31.1 MME CCND1 BCL6
16 composite lymphoma 31.1 MME BCL6
17 primary central nervous system lymphoma 31.0 BCL6 BCL2
18 lymphoma, mucosa-associated lymphoid type 31.0 MYC MME CCND1 BCL6 BCL2 BCL10
19 reticulosarcoma 30.9 MYC BCL6 BCL2
20 nodular lymphocyte predominant hodgkin lymphoma 30.9 CCND1 BCL6
21 t-cell/histiocyte rich large b cell lymphoma 30.8 MME BCL6
22 peripheral t-cell lymphoma 30.8 MME CCND1 BCL6
23 intravascular large b-cell lymphoma 30.8 MYC MME BCL6 BCL2
24 breast lymphoma 30.7 MME BCL6
25 prostate lymphoma 30.7 MME BCL6
26 adult lymphoma 30.6 MYC MME BCL6
27 gastrointestinal lymphoma 30.6 MME CCND1 BCL6
28 leukemia, chronic lymphocytic 30.6 MYC MME MIR338 MIR181A1 MIR155 CCND1
29 ovarian lymphoma 30.4 MME BCL6
30 bone lymphoma 30.4 MME BCL6
31 t-cell lymphoblastic leukemia/lymphoma 30.4 MYC MIR106A CCND1 BCL2
32 gray zone lymphoma 30.4 MME BCL6
33 gallbladder lymphoma 30.3 MME CCND1 BCL6
34 mature b-cell neoplasm 30.3 MYC MME MIR155 CCND1 BCL6 AICDA
35 plasmacytoma 30.2 MYC CCND1 AICDA
36 ductal carcinoma in situ 30.2 MYC MME CCND1
37 leukemia, acute lymphoblastic 30.2 MYC MME MIR210 MIR155 MIR149 BCL6
38 peripheral nervous system disease 30.1 MYC MIR338 MIR181A1 MIR149 CCND1
39 skin melanoma 30.0 MYC MIR149 MIR106A CCND1
40 testicular lymphoma 30.0 MME BCL6
41 in situ carcinoma 29.8 MYC MIR181A1 MIR139 CCND1
42 hematologic cancer 29.7 MIR181A1 MIR155 MIR149 MIR106A
43 immune deficiency disease 29.6 MIR210 MIR181A1 MIR155 BCL6 AICDA
44 acute promyelocytic leukemia 29.5 MYC MIR210 MIR181A1 CCND1 BCL6 BCL2
45 diffuse large b-cell lymphoma 29.4 MYC MME MIR320A MIR210 MIR181A1 MIR155
46 central nervous system disease 29.3 MIR338 MIR210 MIR181A1 MIR155
47 prostate disease 29.3 MIR330 MIR181A1 MIR149 MIR139
48 squamous cell carcinoma, head and neck 29.2 MYC MIR210 MIR155 MIR149 MIR139 CCND1
49 leukemia, acute myeloid 29.0 MYC MME MIR338 MIR330 MIR320A MIR210
50 melanoma 28.9 MYC MIR338 MIR210 MIR181A1 MIR149 MIR139

Graphical network of the top 20 diseases related to Follicular Lymphoma:



Diseases related to Follicular Lymphoma

Symptoms & Phenotypes for Follicular Lymphoma

Human phenotypes related to Follicular Lymphoma:

31 (show all 12)
# Description HPO Frequency HPO Source Accession
1 fever 31 hallmark (90%) HP:0001945
2 lymphoma 31 hallmark (90%) HP:0002665
3 weight loss 31 hallmark (90%) HP:0001824
4 mediastinal lymphadenopathy 31 hallmark (90%) HP:0100721
5 night sweats 31 hallmark (90%) HP:0030166
6 splenomegaly 31 frequent (33%) HP:0001744
7 fatigue 31 frequent (33%) HP:0012378
8 lymphedema 31 occasional (7.5%) HP:0001004
9 meningitis 31 occasional (7.5%) HP:0001287
10 abnormality of the peritoneum 31 occasional (7.5%) HP:0002585
11 pleural effusion 31 occasional (7.5%) HP:0002202
12 skin nodule 31 occasional (7.5%) HP:0200036

Drugs & Therapeutics for Follicular Lymphoma

Drugs for Follicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Neuroprotective Agents Phase 4
2
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
3
Chlorambucil Approved Phase 3 305-03-3 2708
4
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
5
Carmustine Approved, Investigational Phase 3 154-93-8 2578
6
Melphalan Approved Phase 3 148-82-3 4053 460612
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
9
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
10
Lenograstim Approved, Investigational Phase 3 135968-09-1
11
tannic acid Approved Phase 3 1401-55-4
12
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
13
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
14
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
15
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
16
Teniposide Approved Phase 3 29767-20-2 34698
17
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
18
Promethazine Approved, Investigational Phase 3 60-87-7 4927
19
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
20
Acetaminophen Approved Phase 3 103-90-2 1983
21
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
22
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
23
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
24
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
27
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
28
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
29
Idelalisib Approved Phase 3 870281-82-6
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
32
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
33
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
34
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
35
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
36
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
37
Pixantrone Approved, Investigational Phase 3 144510-96-3
38
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
40
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
41
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
43
Fotemustine Investigational Phase 3 92118-27-9
44
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
45
Galiximab Investigational Phase 3 357613-77-5
46 Anti-Retroviral Agents Phase 2, Phase 3
47 Anti-HIV Agents Phase 2, Phase 3
48 Reverse Transcriptase Inhibitors Phase 2, Phase 3
49 Etoposide phosphate Phase 3
50 Immunosuppressive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 583)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma Active, not recruiting NCT03817853 Phase 4 Obinutuzumab;Bendamustine;Cyclophosphamide;Doxorubicin;Prednisone/Prednisolone/Methylprednisolone;Vincristine
3 Prospective Multicenter Study: Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma Unknown status NCT02423837 Phase 3 Rituximab, bendamustine
4 A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma Unknown status NCT02260804 Phase 3
5 MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA Unknown status NCT00435955 Phase 3 Rituximab
6 Phase III Multicentric IIL Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Treatment of Patients With Stage II-IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
7 Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
8 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
9 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
10 Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial Unknown status NCT00028691 Phase 3 chlorambucil
11 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
12 Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
13 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
14 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Completed NCT02213263 Phase 3
15 Rituximab + Standard CHOP (R・S-CHOP) vs Rituximab+ Bi-weekly CHOP (R・Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
16 An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma Completed NCT01059630 Phase 3 Obinutuzumab;Bendamustine
17 A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma Completed NCT02809053 Phase 3
18 A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma Completed NCT02162771 Phase 3 Cyclophosphamide;Vincristine;Prednisone
19 A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen Completed NCT02569996 Phase 3 Rituximab
20 Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy Completed NCT00140582 Phase 3 Rituximab
21 Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy Completed NCT00003204 Phase 3 cyclophosphamide;fludarabine phosphate;vincristine sulfate;prednisone
22 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
23 Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden Completed NCT00696735 Phase 3
24 A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
25 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
26 FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden Completed NCT00136552 Phase 3 rituximab
27 A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
28 Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial Completed NCT00185393 Phase 3
29 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
30 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
31 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
32 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
33 A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
34 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
35 A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV Completed NCT01200758 Phase 3 Rituximab SC;Rituximab IV;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone/Prednisolone
36 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
37 Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial Completed NCT00227695 Phase 3
38 Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy Completed NCT00005589 Phase 3 carmustine;cyclophosphamide;cytarabine;etoposide;melphalan
39 A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-naïve Elderly Patients With Advanced Follicular Lymphoma Completed NCT01144364 Phase 3 rituximab [Mabthera/Rituxan]
40 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
41 A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial Recruiting NCT02438501 Phase 3
42 Dose Optimization Study of Idelalisib in Follicular Lymphoma Recruiting NCT02536300 Phase 3 Idelalisib
43 A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma Recruiting NCT03976102 Phase 3
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Recruiting NCT04680052 Phase 3 tafasitamab;rituximab;lenalidomide;placebo
45 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE) Recruiting NCT02947347 Phase 3 ibrutinib;placebo to match ibrutinib;rituximab;ibrutinib;placebo to match ibrutinib;placebo to match ibrutinib
46 A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma Recruiting NCT04224493 Phase 3 Tazemetostat;Placebo oral tablet
47 Efficacy of Consolidative Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Limited-stage Follicular Lymphoma: Wuhan University Cancer Center -NHL01 Trial Recruiting NCT02449252 Phase 3 cyclophosphamide;doxorubicin;vincristine;prednisone
48 A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements Recruiting NCT04799275 Phase 2, Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Oral Azacitidine;Prednisone;Vincristine Sulfate
49 A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT). Recruiting NCT02390869 Phase 3 R2-MANT;R-MANT
50 ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Supplemental Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab Recruiting NCT03078855 Phase 3

Search NIH Clinical Center for Follicular Lymphoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ibritumomab tiuxetan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Follicular Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, follicular

Genetic Tests for Follicular Lymphoma

Genetic tests related to Follicular Lymphoma:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 29

Anatomical Context for Follicular Lymphoma

MalaCards organs/tissues related to Follicular Lymphoma:

40
Bone Marrow, B Cells, T Cells, Lymph Node, Bone, Spleen, Breast

Publications for Follicular Lymphoma

Articles related to Follicular Lymphoma:

(show top 50) (show all 6530)
# Title Authors PMID Year
1
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 61 47
18537969 2008
2
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
3
Prominent Dutcher body formation in a case of follicular lymphoma with BCL6 gene rearrangement and intact BCL2 gene. 54 61
20069653 2010
4
Rituximab inhibits B-cell receptor signaling. 54 61
19965664 2010
5
Mechanisms of chromosomal rearrangement in the human genome. 54 61
20158866 2010
6
Cyclin D1 positive follicular lymphoma. 54 61
19734488 2009
7
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. 54 61
19519691 2009
8
PDTC enables type I TRAIL signaling in type II follicular lymphoma cells. 54 61
18977530 2009
9
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. 61 54
19414675 2009
10
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. 54 61
19363496 2009
11
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. 61 54
19321861 2009
12
Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma. 61 54
19537891 2009
13
Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch. 61 54
19351371 2009
14
The expression of activation induced cytidine deaminase in follicular lymphoma is independent of prognosis and stage. 54 61
19309412 2009
15
Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. 54 61
19207947 2009
16
Follicular lymphoma of the thyroid gland. 54 61
18830125 2009
17
Structure of the wild-type human BCL6 POZ domain. 61 54
19052359 2008
18
Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression. 61 54
18945749 2008
19
Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. 54 61
18925696 2008
20
A novel fusion 5'AFF3/3'BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma. 61 54
18622426 2008
21
BCL6 gene amplification/3q27 gain is associated with unique clinicopathological characteristics among follicular lymphoma without BCL2 gene translocation. 54 61
18500267 2008
22
The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP. 54 61
18556415 2008
23
Treatment of follicular non-Hodgkin's lymphoma: the old and the new. 61 54
18760706 2008
24
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. 61 54
18427151 2008
25
Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event. 61 54
18089500 2008
26
Molecular frequency of BCL2/JH t(14; 18) using PCR among Lebanese patients with follicular lymphoma: another piece of the geographical map revealed. 61 54
17149654 2007
27
High frequency of BCL2 translocation in Thai patients with follicular lymphomas. 54 61
18055344 2007
28
Derivative (3)t(3;18)(q27;q21)t(18;16)(q21;?) involving the BCL2 and BCL6 genes in follicular lymphoma with t(3;14;18)(q27;q32;q21). 61 54
17981218 2007
29
BNIP3 expression in follicular lymphoma. 61 54
17394490 2007
30
Role of the chromobox protein CBX7 in lymphomagenesis. 61 54
17374722 2007
31
Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. 61 54
17295647 2007
32
MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. 61 54
17296585 2007
33
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. 61 54
17256834 2007
34
A novel t(2;3)(p11;q27) in a case of follicular lymphoma. 54 61
17175383 2007
35
BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. 54 61
17150023 2007
36
Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. 61 54
17088997 2006
37
Pathogenetic and clinical implications of non-immunoglobulin ; BCL6 translocations in B-cell non-Hodgkin's lymphoma. 61 54
17142954 2006
38
Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. 54 61
16939500 2006
39
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. 54 61
16983704 2006
40
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. 54 61
17026765 2006
41
[BCL-XL expression and mutation in non-Hodgkin's lymphoma]. 61 54
17096886 2006
42
BCL2 gene abnormalities define distinct clinical subsets of follicular lymphoma. 61 54
16918969 2006
43
Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. 61 54
16893519 2006
44
The bcl-2 major breakpoint region (mbr) possesses transcriptional regulatory function. 61 54
16777355 2006
45
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 54 61
16847683 2006
46
BCR-bound antigen is targeted to exosomes in human follicular lymphoma B-cells. 61 54
16677129 2006
47
Single nucleotide polymorphism in 5'-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma. 61 54
16125304 2006
48
A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. 61 54
16772123 2006
49
Therapeutic lymphoma vaccines: importance of T-cell immunity. 61 54
16827622 2006
50
The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. 61 54
16769579 2006

Variations for Follicular Lymphoma

ClinVar genetic disease variations for Follicular Lymphoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCL10 NM_003921.5(BCL10):c.629_631AAG[2] (p.Glu212del) Microsatellite Pathogenic 6258 rs587776637 GRCh37: 1:85733375-85733377
GRCh38: 1:85267692-85267694
2 BCL10 NM_003921.5(BCL10):c.398dup (p.Ser134fs) Duplication Pathogenic 6257 rs587776636 GRCh37: 1:85733613-85733614
GRCh38: 1:85267930-85267931
3 BCL10 NM_003921.5(BCL10):c.410del (p.Asn137fs) Deletion Pathogenic 6256 rs587776635 GRCh37: 1:85733602-85733602
GRCh38: 1:85267919-85267919
4 BCL10 NM_003921.5(BCL10):c.525_541del (p.Val176fs) Deletion Pathogenic 6255 rs587776634 GRCh37: 1:85733471-85733487
GRCh38: 1:85267788-85267804
5 BCL10 NM_003921.5(BCL10):c.231dup (p.Gly78fs) Duplication Pathogenic 6254 rs587776633 GRCh37: 1:85736415-85736416
GRCh38: 1:85270732-85270733
6 BCL10 NM_003921.5(BCL10):c.427_428dup (p.Glu145fs) Duplication Pathogenic 6253 rs587776632 GRCh37: 1:85733583-85733584
GRCh38: 1:85267900-85267901

Cosmic variations for Follicular Lymphoma:

9 (show top 50) (show all 4019)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM144183945 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.416G>A p.G139D 19:45072541-45072541 0
2 COSM85770123 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 19:45072541-45072541 0
3 COSM149262901 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4136C>T p.T1379M 16:72798546-72798546 0
4 COSM102021008 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1394C>T p.T465M 16:72798546-72798546 0
5 COSM102022947 ZFHX3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,diffuse large B cell lymphoma c.-23-8436G>A p.? 16:72959401-72959401 0
6 COSM87274133 ZFHX3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,diffuse large B cell lymphoma c.745G>A p.G249S 16:72959401-72959401 0
7 COSM149268221 ZFHX3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,diffuse large B cell lymphoma c.745G>A p.G249S 16:72959401-72959401 0
8 COSM87272037 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4136C>T p.T1379M 16:72798546-72798546 0
9 COSM152021784 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1474C>T p.P492S 18:724582-724582 0
10 COSM89892588 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1474C>T p.P492S 18:724582-724582 0
11 COSM136834701 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1489C>T p.P497S 18:724582-724582 0
12 COSM104881227 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
13 COSM101975701 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
14 COSM104234856 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
15 COSM92178757 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 0
16 COSM94288434 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 0
17 COSM108081754 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 0
18 COSM124861325 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1331C>G p.S444* 8:102257672-102257672 0
19 COSM127535674 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8126C>G p.S2709* 8:102257672-102257672 0
20 COSM87437165 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 8:102278924-102278924 0
21 COSM127546467 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6172G>A p.E2058K 8:102278924-102278924 0
22 COSM127061134 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 8:102257672-102257672 0
23 COSM87426596 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8144C>G p.S2715* 8:102257672-102257672 0
24 COSM127073052 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 8:102278924-102278924 0
25 COSM150369017 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4933C>T p.R1645C 16:2088116-2088116 0
26 COSM148995649 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4939C>T p.R1647C 16:2088116-2088116 0
27 COSM150586385 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4930C>T p.R1644C 16:2088116-2088116 0
28 COSM150364733 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4993A>G p.T1665A 16:2088263-2088263 0
29 COSM150323538 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5083A>G p.T1695A 16:2088263-2088263 0
30 COSM136627256 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5029A>G p.T1677A 16:2088263-2088263 0
31 COSM151376044 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5191A>G p.T1731A 16:2088263-2088263 0
32 COSM102633805 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4936C>T p.R1646C 16:2088116-2088116 0
33 COSM87039775 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5197A>G p.T1733A 16:2088263-2088263 0
34 COSM102629191 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4996A>G p.T1666A 16:2088263-2088263 0
35 COSM151378610 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5131C>T p.R1711C 16:2088116-2088116 0
36 COSM148991145 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4999A>G p.T1667A 16:2088263-2088263 0
37 COSM151519737 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5062C>T p.R1688C 16:2088116-2088116 0
38 COSM150328184 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4936C>T p.R1646C 16:2088116-2088116 0
39 COSM110119485 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4828C>T p.R1610C 16:2088116-2088116 0
40 COSM151755180 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5008C>T p.R1670C 16:2088116-2088116 0
41 COSM110113382 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4888A>G p.T1630A 16:2088263-2088263 0
42 COSM90413881 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5128A>G p.T1710A 16:2088263-2088263 0
43 COSM150583324 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4990A>G p.T1664A 16:2088263-2088263 0
44 COSM151752656 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5068A>G p.T1690A 16:2088263-2088263 0
45 COSM101190485 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4852A>G p.T1618A 16:2088263-2088263 0
46 COSM149819699 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5005C>T p.R1669C 16:2088116-2088116 0
47 COSM147711561 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5008C>T p.R1670C 16:2088116-2088116 0
48 COSM87045821 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5137C>T p.R1713C 16:2088116-2088116 0
49 COSM90419991 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5068C>T p.R1690C 16:2088116-2088116 0
50 COSM136632907 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4969C>T p.R1657C 16:2088116-2088116 0

Copy number variations for Follicular Lymphoma from CNVD:

7 (show top 50) (show all 76)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13361 1 1 12700000 Copy number Follicular lymphoma
2 13749 1 1 27800000 Loss Follicular lymphoma
3 15761 1 119415209 120497765 Amplification NOTCH2 Follicular lymphoma
4 17512 1 143222462 153482569 Copy number ADAM15 Follicular lymphoma
5 17513 1 143222462 153482569 Copy number BCL9 Follicular lymphoma
6 17514 1 143222462 153482569 Copy number IL6R Follicular lymphoma
7 17515 1 143222462 153482569 Copy number MCL1 Follicular lymphoma
8 17516 1 143222462 153482569 Copy number PIAS3 Follicular lymphoma
9 17517 1 143222462 153482569 Copy number TNFAIP8L2 Follicular lymphoma
10 20608 1 153300000 154800000 Gain Follicular lymphoma
11 21393 1 158419998 161795584 Copy number DDR2 Follicular lymphoma
12 21394 1 158419998 161795584 Copy number PEX19 Follicular lymphoma
13 21395 1 158419998 161795584 Copy number UHMK1 Follicular lymphoma
14 25231 1 185800000 214500000 Gain Follicular lymphoma
15 54389 11 43400000 52900000 Gain Follicular lymphoma
16 61270 11 97200000 110400000 Gain Follicular lymphoma
17 65472 12 18053500 31175376 Amplification KRAS Follicular lymphoma
18 65473 12 18053500 31175376 Amplification PIK3C2G Follicular lymphoma
19 65474 12 18053500 31175376 Amplification RASSF8 Follicular lymphoma
20 65475 12 18053500 31175376 Amplification RERGL Follicular lymphoma
21 65476 12 18053500 31175376 Amplification SSPN Follicular lymphoma
22 67780 12 44600000 56300000 Gain Follicular lymphoma
23 69831 12 56316396 72147648 Copy number CDK4 Follicular lymphoma
24 69832 12 56316396 72147648 Copy number DYRK2 Follicular lymphoma
25 69833 12 56316396 72147648 Copy number FRS2 Follicular lymphoma
26 69834 12 56316396 72147648 Copy number IL22 Follicular lymphoma
27 69835 12 56316396 72147648 Copy number MDM2 Follicular lymphoma
28 69836 12 56316396 72147648 Copy number OS9 Follicular lymphoma
29 69837 12 56316396 72147648 Copy number RAB21 Follicular lymphoma
30 69838 12 56316396 72147648 Copy number RAP1B Follicular lymphoma
31 69839 12 56316396 72147648 Copy number RASSF3 Follicular lymphoma
32 69840 12 56316396 72147648 Copy number TBK1 Follicular lymphoma
33 69841 12 56316396 72147648 Copy number TSPAN31 Follicular lymphoma
34 69842 12 56316396 72147648 Copy number WIF1 Follicular lymphoma
35 69843 12 56316396 72147648 Copy number YEATS4 Follicular lymphoma
36 71140 12 67700000 71500000 Gain Follicular lymphoma
37 74580 13 109100000 114142980 Loss Follicular lymphoma
38 79541 13 73300000 79000000 Gain Follicular lymphoma
39 88260 14 88900000 106368585 Loss Follicular lymphoma
40 88262 14 88900000 106368585 Translocation Follicular lymphoma
41 92360 15 40100000 102531392 Loss Follicular lymphoma
42 97239 16 1 16700000 Gain Follicular lymphoma
43 106783 17 1 22200000 Deletion Follicular lymphoma
44 106829 17 1 24000000 Loss Follicular lymphoma
45 107553 17 15900000 22200000 Gain Follicular lymphoma
46 111280 17 35400000 47600000 Gain Follicular lymphoma
47 118113 17 7571720 7590868 Mutation TP53 Follicular lymphoma
48 119191 18 1 59800000 Gain Follicular lymphoma
49 120855 18 33040900 33600413 Amplification CELF4 Follicular lymphoma
50 121287 18 41800000 59800000 Translocation Follicular lymphoma

Expression for Follicular Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Follicular Lymphoma patients vs. healthy controls: 35 (show top 50) (show all 56)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCRLA Fc receptor like A Intestine + 6.40 0.000
2 SERPINA9 serpin family A member 9 Intestine + 5.98 0.000
3 VPREB3 V-set pre-B cell surrogate light chain 3 Intestine + 5.82 0.000
4 STAG3 stromal antigen 3 Intestine + 5.61 0.000
5 SNX22 sorting nexin 22 Intestine + 5.59 0.000
6 NLRP4 NLR family pyrin domain containing 4 Intestine + 4.89 0.004
7 LTF lactotransferrin Intestine + 4.72 0.001
8 FCER2 Fc fragment of IgE receptor II Intestine + 4.70 0.000
9 AIM2 absent in melanoma 2 Intestine + 4.66 0.000
10 P2RX5 purinergic receptor P2X 5 Intestine + 4.54 0.000
11 BFSP2 beaded filament structural protein 2 Intestine + 4.33 0.000
12 DOK7 docking protein 7 Intestine + 4.29 0.000
13 KLHL14 kelch like family member 14 Intestine + 4.26 0.000
14 GPR18 G protein-coupled receptor 18 Intestine + 4.26 0.000
15 PAX5 paired box 5 Intestine + 4.21 0.000
16 CNR1 cannabinoid receptor 1 Intestine + 4.15 0.001
17 PMCH pro-melanin concentrating hormone Intestine + 4.09 0.000
18 AFF3 AF4/FMR2 family member 3 Intestine + 4.02 0.000
19 MMP12 matrix metallopeptidase 12 Intestine + 3.94 0.001
20 LOC613266 uncharacterized LOC613266 Intestine + 3.92 0.000
21 C17orf99 chromosome 17 open reading frame 99 Intestine + 3.88 0.003
22 PCDHGB3 protocadherin gamma subfamily B, 3 Intestine + 3.82 0.002
23 TMEM156 transmembrane protein 156 Intestine + 3.81 0.000
24 FCRL2 Fc receptor like 2 Intestine + 3.76 0.001
25 SCIMP SLP adaptor and CSK interacting membrane protein Intestine + 3.75 0.000
26 CCL17 C-C motif chemokine ligand 17 Intestine + 3.73 0.004
27 VNN2 vanin 2 Intestine + 3.71 0.000
28 OR13A1 olfactory receptor family 13 subfamily A member 1 Intestine + 3.59 0.001
29 PCDHGB2 protocadherin gamma subfamily B, 2 Intestine + 3.53 0.001
30 CYP4F11 cytochrome P450 family 4 subfamily F member 11 Intestine - 3.53 0.015
31 APOBEC2 apolipoprotein B mRNA editing enzyme catalytic subunit 2 Intestine - 3.51 0.003
32 KIAA1549L KIAA1549 like Intestine + 3.45 0.003
33 TCL6 T cell leukemia/lymphoma 6 Intestine + 3.41 0.005
34 AFF2 AF4/FMR2 family member 2 Intestine + 3.35 0.006
35 CD37 CD37 molecule Intestine + 3.24 0.000
36 IL22RA2 interleukin 22 receptor subunit alpha 2 Intestine + 3.22 0.012
37 ST6GAL1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 Intestine + 3.22 0.001
38 ARHGAP24 Rho GTPase activating protein 24 Intestine + 3.21 0.001
39 PLEKHG7 pleckstrin homology and RhoGEF domain containing G7 Intestine + 3.20 0.000
40 CAPN14 calpain 14 Intestine + 3.20 0.002
41 SPANXN3 SPANX family member N3 Intestine - 3.18 0.002
42 SMIM43 small integral membrane protein 43 Intestine + 3.16 0.002
43 RPS16P5 ribosomal protein S16 pseudogene 5 Intestine + 3.15 0.000
44 SLC7A10 solute carrier family 7 member 10 Intestine + 3.15 0.002
45 SLC5A12 solute carrier family 5 member 12 Intestine - 3.13 0.000
46 PCDH11Y protocadherin 11 Y-linked Intestine + 3.13 0.001
47 BEND4 BEN domain containing 4 Intestine + 3.13 0.001
48 PCDHGA5 protocadherin gamma subfamily A, 5 Intestine + 3.12 0.006
49 MYBL1 MYB proto-oncogene like 1 Intestine + 3.11 0.008
50 PDCD1 programmed cell death 1 Intestine + 3.09 0.001
Search GEO for disease gene expression data for Follicular Lymphoma.

Pathways for Follicular Lymphoma

GO Terms for Follicular Lymphoma

Cellular components related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR338 MIR320A MIR301A MIR210 MIR181A1 MIR155

Biological processes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.76 MYC CCND1 BCL6 BCL2
2 regulation of apoptotic process GO:0042981 9.73 MIR155 BCL6 BCL2 BCL10
3 negative regulation of cell migration GO:0030336 9.62 MIR338 MIR320A MIR149 BCL2
4 B cell differentiation GO:0030183 9.58 BCL6 BCL2 AICDA
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.54 MIR320A MIR155 MIR149
6 response to iron ion GO:0010039 9.48 CCND1 BCL2
7 miRNA mediated inhibition of translation GO:0035278 9.46 MIR210 MIR181A1 MIR155 MIR106A
8 negative regulation of interleukin-8 production GO:0032717 9.43 MIR181A1 MIR155 MIR106A
9 gene silencing by miRNA GO:0035195 9.32 MIR338 MIR330 MIR320A MIR301A MIR210 MIR181A1
10 negative regulation of interleukin-6 production GO:0032715 9.26 MIR338 MIR181A1 MIR155 MIR149

Molecular functions related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR338 MIR330 MIR320A MIR301A MIR210 MIR181A1
2 mRNA 3'-UTR binding GO:0003730 9.26 MIR338 MIR181A1 MIR139 MIR106A

Sources for Follicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD